Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://smithonstocks.com/denial-of-the-motion-to-dismiss-in-northwest-biotherapeutics-lawsuit-against-seven-wall-street-market-makers-for-spoofing-would-be-a-major-catalyst-for-the-company
Thanks bio!! Any questions??!! "well, do ya, punk?"
Thanks Lykiri,
Any way to access:
"attached is a photo of Owains daily and night routine of drugs and supplements" as you mentioned in your post. I would love to compare "notes" with him.
I had Whipple surgery in Nov 2012 (for 3cm Pancreatic Neuroendocrine tumor); 5 years later, multiple (20+) mets showed up in my liver. After getting rid of those with radioembolization treatments in 2018, I started on long list of supplements and meds and been in remission since!!
flipper44, do we know if these other countries (Israel, Japan, India, China, Australia, etc) have their own RAs that would require NWBO to submit "approval" requests/packages Also, wonder who, at NWBO is putting in all the hours on this, seemingly, proliferation of patent submssions and approvals? TIA
"one of Citadel’s investment arm’s largest holdings" Hmmm!
Done!! LPosner@cohenmilstein.com
How did that benefit citi?
Recent article, but you have to question their research based on this excerpt re Dendritic Cell vaccines:
"Dendritic cell (DC) vaccines are potentially effective in the treatment of GB, though their development is quite a challenging process requiring elaborate facilities to safely extract and pulse DCs with the tumor components. This limits the ability of DC vaccines to be rapidly scaled for broader utilization."
"I'm melting! Melting! Oh, what a world, what a world! Who would have thought a good little girl like you could destroy my beautiful wickedness!"
Crash,
good news, bad news, no bfd?
👍️ correct
Yes, I asked DI yesterday -- NR.
Kap10jak, yaaasss!! "I'm pickin' up good vibrations, NWBO's giving me the excitations"
Yaaasss!! Thanks StonkMaster!!
Redmond, WA (February 26, 2024) – The End Brain Cancer Initiative (EBCI) is advocating for FDA approval of DCVax®-L, a novel treatment for Glioblastoma (GBM) brain tumors, in anticipation of submittal of the application for FDA approval by Northwest Biotherapeutics. The End Brain Cancer Initiative is dedicated to ensuring patients have full access to FDA approved treatments and many different treatment options, such as advanced diagnostics and clinical trials, and now DCVax®-L, which has demonstrated increased survivorship and Quality of Life in approximately 20% of the GBM patients who participated in clinical trials for this treatment.
“The FDA needs to understand that not one treatment is viable for this disease as Glioblastoma (GBM) quickly becomes resistant to all treatment. Therefore, patients need to have multiple and varied treatment options so that when their tumor becomes resistant to a treatment, they are able to quickly pivot to another FDA approved treatment option,” said Dellann Elliott Mydland, End Brain Cancer Initiative (EBCI), CEO & President. “In order to provide brain cancer patients multiple treatment options, increase patient Quality of Life, provide HOPE for this patient community, and encourage additional investment by pharma/biotech companies into GBM research, the FDA needs to approve multiple treatment options for this patient population. Currently, there are a very limited number of treatment options FDA approved for this disease, which limits patient access and decreases survivorship. EBCI and I are working hard to advocate for and expand access to additional treatment options and improve Standard of Care for the brain tumor and brain cancer patient community.”
Call to Action: Team up with the End Brain Cancer Initiative to advocate for FDA approval for DCVax®-L. Raise your voice by sharing your story at app.hatchbuck.com/OnlineForm/936….
DCVax®-L represents a novel form of immunotherapy classified as a dendritic cell vaccine. Developed by Northwest Biotherapeutics, this personalized vaccine is crafted from each patient’s unique dendritic cells, a crucial component aiding the immune system in recognizing and combatting cancer cells. The intricate process involves isolating immune cells from the patient’s blood, exposing them to tumor cells, and enabling dendritic cells to recognize specific markers associated with the patient’s tumor cells. Once re-introduced into the patient’s system, these “educated” dendritic cells recruit and instruct other immune cells, known as T-cells, to travel to the tumor site and attack cancerous cells. Learn more at nwbio.com.
The End Brain Cancer Initiative is a 501(c)3 non-profit patient organization focused on disease education, awareness, outreach and increasing patient access. The End Brain Cancer Initiative, formerly known as the Chris Elliott Fund, is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides this patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with medical teams. Learn more about and support the End Brain Cancer Initiative’s work and mission at EndBrainCancer.org.
Dellann Elliott Mydland
End brain cancer Initiative
+1 425-444-2215
Yaaasss!! Thanks StonkMaster!!
Redmond, WA (February 26, 2024) – The End Brain Cancer Initiative (EBCI) is advocating for FDA approval of DCVax®-L, a novel treatment for Glioblastoma (GBM) brain tumors, in anticipation of submittal of the application for FDA approval by Northwest Biotherapeutics. The End Brain Cancer Initiative is dedicated to ensuring patients have full access to FDA approved treatments and many different treatment options, such as advanced diagnostics and clinical trials, and now DCVax®-L, which has demonstrated increased survivorship and Quality of Life in approximately 20% of the GBM patients who participated in clinical trials for this treatment.
“The FDA needs to understand that not one treatment is viable for this disease as Glioblastoma (GBM) quickly becomes resistant to all treatment. Therefore, patients need to have multiple and varied treatment options so that when their tumor becomes resistant to a treatment, they are able to quickly pivot to another FDA approved treatment option,” said Dellann Elliott Mydland, End Brain Cancer Initiative (EBCI), CEO & President. “In order to provide brain cancer patients multiple treatment options, increase patient Quality of Life, provide HOPE for this patient community, and encourage additional investment by pharma/biotech companies into GBM research, the FDA needs to approve multiple treatment options for this patient population. Currently, there are a very limited number of treatment options FDA approved for this disease, which limits patient access and decreases survivorship. EBCI and I are working hard to advocate for and expand access to additional treatment options and improve Standard of Care for the brain tumor and brain cancer patient community.”
Call to Action: Team up with the End Brain Cancer Initiative to advocate for FDA approval for DCVax®-L. Raise your voice by sharing your story at app.hatchbuck.com/OnlineForm/936….
DCVax®-L represents a novel form of immunotherapy classified as a dendritic cell vaccine. Developed by Northwest Biotherapeutics, this personalized vaccine is crafted from each patient’s unique dendritic cells, a crucial component aiding the immune system in recognizing and combatting cancer cells. The intricate process involves isolating immune cells from the patient’s blood, exposing them to tumor cells, and enabling dendritic cells to recognize specific markers associated with the patient’s tumor cells. Once re-introduced into the patient’s system, these “educated” dendritic cells recruit and instruct other immune cells, known as T-cells, to travel to the tumor site and attack cancerous cells. Learn more at nwbio.com.
The End Brain Cancer Initiative is a 501(c)3 non-profit patient organization focused on disease education, awareness, outreach and increasing patient access. The End Brain Cancer Initiative, formerly known as the Chris Elliott Fund, is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides this patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with medical teams. Learn more about and support the End Brain Cancer Initiative’s work and mission at EndBrainCancer.org.
Dellann Elliott Mydland
End brain cancer Initiative
It's PR Tuesday!! Let's go NWBO--nothing but great news in every PR since "Halt" in 2015 -- which actually was not "bad news." No reason to stop now!!!!
Right on, George!!
And let's not forget the side effects warning:
"The most frequent side effects reported in the NALIRIFOX group included neutropenia (low levels of a type of immune cell called neutrophils) and hypokalemia (low potassium level), and gastrointestinal disorders like diarrhea and nausea."
Found this on my Pancreatic Cancer support group website -- FDA approved a combo treatment for metastatic Pancreatic Cancer, using 3 previously approved chemotherapy drugs. Shows improved OS of about 2 months.
https://pancan.org/news/fda-approves-new-first-line-treatment-option-for-metastatic-pancreatic-cancer-what-you-need-to-know/?s_src=progress+matters&s_subsrc=progress+matters_newsletter_zz_email_all+constituents&utm_source=newsletter&utm_medium=email&utm_campaign=progress+matters&utm_term=all+constituents&utm_content=zz
Murcidencel
Good news, bad news, no news?
Here is a short list :
- MAA approval
- Other RA submissions
- Combo partnerships with big financing from partners
- CRL global manufacturing partnership
- Peer reviewed, Nature.com article (50% overall survival at 8 years with DCVax and Poly-ICLC combo)
- Uplist, with retail "whales" and major institutional investors coming on board
- MTD dismissed with multi- billion dollar settlement(s) (or discovery)
- U.K. 7-year Compassionate use data released for 400+ patients (shows agnostic applicability and outstanding survival stats, with no side effects)
- National and international media rollout of NWBO and DCVax journey (LP and LP interviews)
Just to name a few!!!!!!!
Aahaaa!! One of my favorite midnight (sleep like a baby) snacks. My father (Pasquale) was born in 1925 on Easter Sunday, just east of Rome (Abruzzi)! Mom's family is from Milan -- viva pasta!
It's not been discussed here much, but as we all know, NWBO only has about 20 employees. Any thoughts, concerns, comments. Is it a "red flag" for something good/bad? With an "imminent" approvel only week/months away, for a personalized cell therapy (vaccine), should they be hiring staff (sales, ops, finance, research/development, etc)? TIA fir your thoughts, comments, concerns, etc.
GGB -- don't make me giddy !
Ok, let's GOOOOO!!
Someone correct me if I'm wrong, but I believe, Aug 2024 for completion of Phase III. Preliminary phase II (outstanding) results were published in Nature.com pre-print -- awaiting full publication.
StonkMaster!! Is this what I think it is??!! Acceptance/Validation!!??
Great question -- I don't know! Should we read anything into that? I did not identify myself as an investor, but did respond directly to him, "good to see you are following NWBO."
hope, do we know when this article was published -- has it been around?
Is this THE Nature.com article we've been expecting (as follow-up to the Nature.com pre-print published a few months ago)? TIA
Thier employer will be implementing a major RIF very soon!!🤧
Great timing for this article to be published -- let's get over a $1 next week and stay there!! GLTA
So ski,
Do we think the DCVax-L/Keytruda combo trial is sponsored and paid for by UCLA/NIH (same with poly ICLC)? If yes, then this may explain why neither NWBO nor Merck (and Oncovir) have provided any comments/PRs/updates re the combo trials? Obviously, NWBO and Merck (and Oncovir) have been taking copius notes
So, all is good!! MHRA had 14 days to deny submission, but did not (no news, is good news)! By definition, we have "acceptance."
Been away from the board today. Was wondering if there were any discussions re the attached news piece? Thought NWBO had numerous patents on its DCVax platform and associated manufacturing technology -- their process sounds eerily familiar!!??
https://www.businesswire.com/news/home/20240102095438/en/Diakonos-Oncology-Completes-Phase-1-Glioblastoma-Trial-Recruitment-Receives-FDA-Orphan-Drug-Designation
newman, newman, newman 🙈🙉🙊